Toagosei Co., Ltd.
Notice Regarding the Status of Treasury Stock Acquisition (Acquisition of Treasury Stock Based on the Provisions of Article 165, Paragraph 2 of the Companies Act)
From February 13 to February 28, 2026, Towa Pharmaceutical Co., Ltd. acquired 1,150,000 shares of treasury stock at a total value of 2,105,075,000 yen.
Key Figures
- Total Number of Shares Acquired: 1,150,000 shares (February 13, 2026 – February 28, 2026)
- Total Acquisition Price: 2,105,075,000 yen (same period)
- Maximum Authorized Acquisition Shares: 2,000,000 shares (Board resolution dated February 12, 2026)
AI要約
Overview of Capital Policy
Towa Pharmaceutical Co., Ltd. conducted a treasury stock acquisition based on the Board of Directors resolution dated February 12, 2026, in accordance with the provisions of Article 165, Paragraph 3 of the Companies Act. Between February 13 and February 28, 2026, the company purchased 1,150,000 common shares through market purchases on the Tokyo Stock Exchange at a total price of 2,105,075,000 yen. The maximum allowable acquisition is 2,000,000 shares, with an acquisition cost ceiling of 3 billion yen, and the acquisition period is set from February 13, 2026, to December 31, 2026.
Impact on Shareholders and Future Outlook
This acquisition corresponds to approximately 1.86% of the total issued shares excluding treasury stock. The treasury stock acquisition is expected to suppress dilution and enhance shareholder value. The company plans to continue acquiring treasury stock within the authorized limit as part of its capital policy, positioning this action as a move to strengthen shareholder returns.
